Is Cytotron therapy FDA approved?

Cytotron holds FDA Breakthrough Device Designation for certain solid tumor indications, including breast, liver, and pancreatic cancers. This designation expedites clinical trial development. It is currently available at select clinics outside the United States, including Pathways to Heal in Mexico City.

What types of cancer does Cytotron treat?

Cytotron is designed for solid tumors that can be mapped via MRI. It has been studied in breast cancer, liver cancer, pancreatic cancer, prostate cancer, and other solid tumor types. Blood malignancies such as leukemia are not candidates for this approach.

Is Cytotron therapy painful or invasive?

No. Cytotron therapy is entirely non-invasive. Patients lie within the device while it delivers radiofrequency waves to the treatment area. There is no ionizing radiation, no surgery, no needles, and no downtime. Most patients report no discomfort during treatment.

Where can I receive Cytotron therapy?

Cytotron therapy is available at Pathways to Heal in Mexico City, under the direction of Dr. Carlos Armando Sosa Luna. Treatment is offered as part of a comprehensive 4-week integrative oncology program that combines Cytotron with NK cell immunotherapy.

What Is Cytotron Therapy and How Does It Treat Cancer?

Q: What is Cytotron therapy?

Cytotron is a medical device that uses Rotational Field Quantum Magnetic Resonance (RFQMR) technology to deliver precisely focused, non-ionizing radiofrequency waves to cancer cells. It disrupts the transmembrane potential of cancer cells, reactivates the p53 tumor suppressor pathway, and induces apoptosis — programmed cell death — without harming surrounding healthy tissue.

Cancer cells are defined by one thing above all else: uncontrolled division. Cytotron therapy works by interrupting that process at its most fundamental level — the cell membrane — using precisely focused radiofrequency energy, without radiation, surgery, or toxic side effects.

What Is Cytotron Therapy?

Cytotron is a medical device developed by the Scalene Cybernetics Institute in India. It uses a technology called Rotational Field Quantum Magnetic Resonance (RFQMR) — a form of non-ionizing, non-thermal radiofrequency energy delivered within a controlled magnetic field to disrupt the biological behavior of cancer cells.

Unlike conventional radiotherapy, which uses high-energy ionizing radiation to damage DNA in both cancer and healthy cells, Cytotron delivers low-energy radiofrequency waves precisely targeted to the tumor. It does not burn, cut, or poison. It disrupts — targeting the electrical environment cancer cells depend on to survive and replicate.

The device resembles an MRI scanner. Patients lie within a cylindrical chamber while RFQMR beams are aimed at the tumor site. Treatment sessions are typically 60 minutes, conducted daily over a course of weeks.

FDA

Breakthrough Device Designation: Cytotron has received FDA Breakthrough Device Designation for certain solid tumor indications — including breast, liver, and pancreatic cancers. This status expedites clinical development and signals significant promise in early-stage evidence. It is currently available at select clinics outside the United States.

How Does Cytotron Work?

To understand how Cytotron affects cancer, it helps to understand what makes cancer cells different at the membrane level. Healthy cells maintain a specific electrical charge difference between the inside and outside of the cell — called Transmembrane Potential (TMP). Cancer cells have a characteristically lower TMP, and this altered electrical environment drives many of their most dangerous properties: rapid division, resistance to apoptosis (programmed death), and immune evasion.

Cytotron works by correcting and destabilizing this altered electrical environment through four sequential mechanisms:

MRI-Based Targeting

Before treatment begins, MRI imaging maps the tumor's proton density. This data is used to program the Cytotron device to focus RFQMR energy specifically on cancer tissue, sparing surrounding healthy cells.

Transmembrane Disruption

RFQMR waves alter the Transmembrane Potential (TMP) and Piezo 1 ion channels of cancer cells — disrupting the electrical signals that drive uncontrolled division. Cancer cells depend on this environment to proliferate; once disrupted, division stalls.

p53 Reactivation

Cytotron reactivates the p53 tumor suppressor pathway — often called the "guardian of the genome." In most cancers, p53 has been silenced, removing the cell's primary stop signal. Restoring p53 function is one of oncology's most important therapeutic goals.

Apoptosis — Programmed Cell Death

With TMP disrupted and p53 restored, cancer cells receive the signal to self-destruct through natural apoptosis — the body's own orderly cell disposal system. The immune system clears the resulting debris over subsequent weeks, a process that continues long after treatment ends.

"The idea of combining a tumor-stabilizing technology with immune-boosting cell therapy is scientifically interesting and aligns with modern oncology trends — creating a continuous, overlapping anti-tumor assault designed to overcome tumor evasion."

— Integrative Oncology Research Commentary

The Four Key Mechanisms

Cytotron's effects on cancer biology are broad. Understanding each mechanism helps explain why it can affect tumors that have become resistant to conventional therapies:

Cell Cycle Arrest

RFQMR disrupts microtubule formation during mitosis — the process cancer cells use to physically divide. Without functioning microtubules, cell division stops.

Membrane Depolarization

Altering the TMP removes the low-voltage environment cancer cells require. They cannot sustain their hyperproliferative state once the membrane is depolarized.

Tumor Suppression Pathway Restoration

Reactivation of p53 — which cancer silences to achieve immortality — restores the cell's intrinsic ability to identify damage and initiate self-destruction.

Non-Ionizing, Non-Thermal

No DNA damage, no radiation injury, no heat. Cytotron uses low-energy waves that affect cancer-specific biology without triggering the inflammatory cascade of conventional radiation.

What Types of Cancer Can Cytotron Treat?

Cytotron is designed for solid tumors — cancers that form a discrete, locatable mass that can be mapped on MRI. This includes, but is not limited to:

Breast cancer
Liver and hepatocellular carcinoma
Pancreatic cancer
Prostate cancer
Lung cancer (non-small cell)
Colorectal cancer
Cervical and ovarian cancer
Soft tissue and bone sarcomas
Brain tumors (glioblastoma and others)
Head and neck cancers

Blood malignancies such as leukemia and lymphoma — which do not form solid, locatable masses — are generally not candidates for Cytotron therapy, as the device requires a specific anatomical target to focus its energy.

What Is the Patient Experience?

Many patients are surprised by how straightforward Cytotron treatment feels compared to conventional oncology:

No hospitalization required — treatment is outpatient
No anesthesia or sedation
No needles or invasive procedures
No hair loss, nausea, or radiation-related fatigue
60-minute daily sessions over a course of weeks
Patients remain fully awake and comfortable during treatment

Most patients treated at Pathways to Heal undergo Cytotron as part of a 4-week integrative protocol that combines daily Cytotron sessions with NK Cell immunotherapy infusions, nutritional support, and comprehensive clinical monitoring.

Cytotron + NK Cell Therapy: A Synergistic Approach

At Pathways to Heal, Cytotron is rarely used in isolation. It is paired with NK (Natural Killer) Cell immunotherapy — infusions of 35 million to 204 million allogeneic NK cells expanded from umbilical cord blood — creating what Dr. Sosa describes as a two-pronged assault on cancer.

The logic behind the combination is compelling:

Cytotron disrupts and arrests cancer cells at the membrane and cell cycle level — weakening tumor defenses and inducing apoptosis
NK Cells identify and eliminate cancer cells that have been destabilized, as well as circulating tumor cells that may evade Cytotron's range
Together, they create overlapping pressure on the tumor from both physical and immunological directions — making it significantly harder for cancer cells to adapt or escape

First scan results to assess response are typically reviewed at the 2–3 month mark following the start of treatment, allowing time for the immune system to clear apoptotic debris and for imaging to reflect true tumor response.

Am I a Candidate for Cytotron?

Cytotron may be appropriate for you if:

You have a solid tumor that is visible and measurable on MRI
You are currently in active treatment and seeking adjunctive support
You have completed conventional treatment and are seeking integrative follow-on care
Conventional options have been exhausted or declined and you are exploring alternatives
You are in remission and seeking approaches to reduce recurrence risk

The best way to determine candidacy is through a direct case review with Dr. Sosa, who personally evaluates every patient's medical history, imaging, and treatment history before recommending a protocol.

Frequently Asked Questions

Is Cytotron therapy painful?

No. Patients lie within the device in a relaxed position during each 60-minute session. The RFQMR technology produces no heat, no radiation sensation, and no physical discomfort. Most patients read, listen to music, or rest during treatment.

Can Cytotron be used alongside chemotherapy or radiation?

Yes, in many cases. Cytotron is non-ionizing and does not interact with most conventional therapies. Dr. Sosa conducts a full review of concurrent treatments before designing any protocol to ensure compatibility and to avoid any contraindications.

How long does a Cytotron treatment course last?

At Pathways to Heal, the standard protocol is a 4-week residential program with daily Cytotron sessions combined with NK Cell immunotherapy infusions. Some patients return for additional cycles depending on their response and clinical goals.

When will I know if Cytotron is working?

Because apoptosis involves the immune system clearing cellular debris over time, imaging immediately after treatment may not reflect the full picture. The first meaningful scan review typically occurs 2–3 months after the start of treatment. Certain blood markers and tumor indicators may be monitored earlier.

Is Cytotron available in the United States?

Cytotron holds FDA Breakthrough Device Designation, which accelerates its path toward US approval. It is not yet available within US borders but is offered at select international clinics, including Pathways to Heal in Mexico City — accessible via direct flight from most major US cities.

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Cytotron therapy is an investigational treatment. Individual outcomes vary and are not guaranteed. All statistics referenced are drawn from published clinical studies with specific patient populations and limitations. Please consult with a qualified physician before making treatment decisions. Dr. Sosa's team is available for a personal case review.

Ready to Explore Whether Cytotron Is Right for You?

Dr. Sosa personally reviews every case. Submit your medical intake and our team will respond within 24–48 hours.

Request a Free Consultation